People channel feed

A uni­corn built on lies? Founders of Sanofi part­ner may face 20 years in prison for al­leged­ly prof­it­ing from stolen Genen­tech trade se­crets

Just how much are Genentech trade secrets worth?

The storied South San Francisco biotech and Roche subsidiary unearthed a covert operation to profit from years of experience and knowhow when it accused Taiwan’s JHL Biotech of stealing information through one of its senior scientists. JHL, which had scored a pact with Sanofi to market biosimilars of Genentech’s top-selling drugs, has since settled the case and agreed to shut down any related work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Axel Hoos, incoming Scorpion CEO

Ax­el Hoos, the keep­er of the on­col­o­gy flame at Glax­o­SmithK­line, steps away for his next chal­lenge at tiny Scor­pi­on

Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and decided to rebuild anew. Now, watching the pipeline he helped remold finally bear fruit, Hoos is ready for a new challenge — and it will come at a tiny biotech at the frontier of “precision medicine 2.0.”

Hoos will jump ship after a nine-year stint at GSK to helm Scorpion Therapeutics, a stealthy biotech working on identifying and targeting “undruggable” targets in oncology. He will pick up the mantle in August, marking his long-awaited return to biotech and first go at the CEO role.

Jean-Charles Soria (Credit: ESMO)

Scoop: Am­gen re­cruits renowned can­cer drug in­ves­ti­ga­tor Jean-Charles So­ria to lead a grow­ing pipeline play

One of the pioneers in the complete overhaul of oncology R&D over the last 10 years is headed to Amgen.

The pharma giant put out the word on social media that Jean-Charles Soria, the director general of the storied Gustave Roussy Institute in France, is joining LA-based Amgen to lead the oncology therapeutic area as senior vice president.

Soria, who also held a top oncology post with AstraZeneca before returning to the institute at the beginning of 2020, tells us via email that he is “deeply excited” to be joining the company.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Kate Cronin, new Moderna chief brand officer (Ogilvy Health)

Mod­er­na hires a chief brand of­fi­cer to guide vac­cine cam­paigns through 'time of rapid growth'

In the last couple years, Moderna has transformed from a small Cambridge biotech with big dreams into one of the most talked-about drugmakers in the world. In Q1 alone, the company’s mRNA vaccine for Covid-19 pulled in more than $1 billion. Now, it’s beefing up its marketing game.

Moderna is bringing Ogilvy Health veteran Kate Cronin on board as chief brand officer to scale up during “a time of rapid growth,” CEO Stéphane Bancel said Monday.

At biotech's small­est com­pa­nies, fe­male ex­ec­u­tives make up on­ly a frac­tion of C-suite lead­ers — re­port

Despite repeated calls to diversify the biotech industry, women and those in minority groups make up just 14% of board members at public micro- and small-cap companies, according to a new report by the Bedford Group and Transearch.

“Just the total percentage of CEOs [who] are female was much lower than anticipated,” said Darren Raycroft, partner and managing director at the Bedford Group.

For over a decade, the firm has compiled executive compensation reports in other verticals. But for the first time, they’re releasing a report based on 225 public biotech companies in the US with market caps under $2 billion — and what they found was a stark lack of diversity among the highest ranks of the industry.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Christophe Bourdon, Orphazyme

Or­p­hazyme plans to lay off most of its staff fol­low­ing a string of fail­ures for lead 'pipeline-in-a-pro­duc­t'

Danish biopharma Orphazyme has been on a roller coaster of a ride lately, and the company plummeted down a bit further on Monday with the announcement that it will lay off two-thirds of its workforce.

The news comes nearly two months after arimoclomol, the company’s “pipeline-in-a-product,” flopped in ALS. The drug failed to meet primary or secondary endpoints for function and survival. The drug was handed a complete response letter from the FDA two weeks ago, and its stock plummeted 56.39 % to $6.35.

Susan Galbraith (AstraZeneca)

As­traZeneca CEO Pas­cal So­ri­ot taps vet­er­an can­cer re­searcher Su­san Gal­braith for top on­col­o­gy post

When Susan Galbraith joined the cancer R&D team at AstraZeneca in 2010, the pharma giant was undergoing a brutal takedown at the hands of analysts uniformly shaking their heads over one of the weakest pipelines among the majors. Both she and the company persevered, though, and went on to pioneer some of the most successful drug franchises in oncology.

Today, she takes her place as the new EVP of oncology research at AstraZeneca’s new research and development home in Cambridge, UK.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Karen Flynn, Catalent

Q&A: When the pan­dem­ic struck, Catal­en­t's CCO had just joined the team

Karen Flynn came aboard Catalent’s team just in time.

The company was going through a surge of changes, and she had been brought over from her role as CCO of West Pharmaceutical Services to serve in the same capacity for the New Jersey-based CDMO. Then a few months later, the pandemic was in full-force.

Since then, Catalent’s been in hyper-expansion mode. In early May, it acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. Prior to that, the company acquired Belgian CDMO Delphi Genetics, wrapped up the expansion of an already-existing site in Madison, WI and added an ultra-low temperature freezer partner in Sterling. As Emergent has botched millions of doses of AstraZeneca’s vaccine, the company has swooped in to move that production to its Maryland plant as well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.

Peter Bach, new Delfi Diagnostics CMO (Michael Loccisano/Getty Images for New York Times)

Out­spo­ken drug pric­ing re­searcher Pe­ter Bach takes CMO gig at liq­uid biop­sy start­up

After spending more than a decade criticizing the industry over drug pricing, Memorial Sloan Kettering’s outspoken researcher Peter Bach is jumping over to the C-suite of a liquid biopsy startup.

Bach, known for his frank tweets and frequent editorials, is taking the CMO role at Delfi Diagnostics, a Baltimore-based biotech that’s looking for a better way to screen the blood for cancer. The company snagged $100 million at the beginning of the year, and a couple months ago initiated a national trial for lung cancer screening.

Piet Wigerinck, Galapagos

Gala­pa­gos CSO hits the ex­it as the biotech looks to pick up the pieces af­ter FDA's fil­go­tinib re­jec­tion

Months after Galapagos cut away broad swaths of its pipeline following a rejection for Gilead-partnered rheumatoid arthritis drug filgotinib, the biotech will now say goodbye to its longtime chief scientific officer as it considers its options moving ahead.

Piet Wigerinck will step down from his role later this year, the company announced on Tuesday. Wigerinck joined in 2008 as the SVP of development, and became the CSO in 2012. He oversaw the discovery of novel targets through to clinical proof-of-concept studies, led the first clinical research in healthy volunteers and was responsible for two Phase II programs for filgotinib, a JAK inhibitor.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.